Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Am J Transplant ; 13(12): 3215-22, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24266972

RESUMO

The immune cell function assay (ICFA) and de novo anti-donor-specific HLA antibodies (DSA) have been proposed as assays for immune monitoring in renal transplantation, but longitudinal studies examining the modification of both parameters over time and their relation with clinical events are lacking. We prospectively measured longitudinal changes in ICFA and DSA levels in 55 kidney transplant recipients over 3-year follow-up (534 visits) and analyzed their relation with the risk of developing acute rejections or infections. Seven patients (12.7%) developed biopsy-proven acute rejection, and 20 (36.4%) developed viral infections. At 3 years posttransplant, 28% of the patients had developed de novo DSA. ICFA levels peaked at 1-2 months posttransplant (p = 0.005) and leveled off thereafter. They were not associated with the risk of acute rejections, viral infections or development of de novo DSA. Instead, the incidence of de novo DSA was higher in patients who previously had viral infections (adjusted-odds ratio of de novo DSA associated with prior infections: 6.03 [95% CI, 1.64-22.06; p = 0.007]). Our prospective, longitudinal study does not support using ICFA to quantify the immune risk in kidney transplantation. Further studies are needed to confirm the relationship between viral infections and the subsequent development of de novo DSA.


Assuntos
Anticorpos/química , Antígenos HLA/química , Transplante de Rim , Adulto , Linfócitos T CD4-Positivos/imunologia , Feminino , Rejeição de Enxerto , Sobrevivência de Enxerto/imunologia , Teste de Histocompatibilidade , Humanos , Imunossupressores/uso terapêutico , Doadores Vivos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Monitorização Imunológica , Transplante de Pâncreas , Estudos Prospectivos , Risco
2.
J Nephrol ; 29(4): 479-86, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26842624

RESUMO

Immunoglobulin (Ig)M nephropathy (IgMN), known since 1978, is a very controversial clinicopathological entity characterized by IgM diffuse deposits in the mesangium at immunofluorescence whereas light microscop identifies minimal glomerular lesion, hypercellularity and expansion of the mesangium or sclerotic focal, segmental lesion. Clinically, it is a nephrotic syndrome, especially in pediatric patients, or asymptomatic proteinuria and/or isolated hematuria. These characteristics narrowly define IgMN between minimal change disease and focal segmental glomerulosclerosis, so it is not often recognized as a separate pathology. Homogeneous epidemiologic, pathogenetic, clinical or histological data are not available. Recent research on the pathogenetic role of mesangial IgM has, however, renewed interest in IgMN and naturally the controversies.


Assuntos
Glomerulosclerose Segmentar e Focal/patologia , Imunoglobulina M , Glomérulos Renais/patologia , Nefrose Lipoide/patologia , Síndrome Nefrótica/patologia , Imunofluorescência , Humanos , Microscopia Eletrônica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA